Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Contributed by: Business Wire

Logo

Tags

Health

Other Consumer

Consumer

Women

Other Health

Pharmaceutical

Biotechnology

Organon & Co.

More Like This

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

PR Newswire associated0

Vueway® (Gadopiclenol) Receives Positive CHMP Opinion

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

PR Newswire associated0

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union